Predicting the acute-phase response fever risk in bisphosphonate-naive osteoporotic patients receiving their first dose of zoledronate.

Lu, Ke; Shi, Qin; Gong, Ya-Qin; Shao, Jia-Wei; Li, Chong

Lu, Ke; Shi, Qin; Gong, Ya-Qin; Shao, Jia-Wei; Li, Chong.

Afiliação

Lu K; Department of Orthopedics, Affiliated Kunshan Hospital of Jiangsu University, Gusu School, Nanjing Medical University, No. 91 West of Qianjin Road, Suzhou, 215300, Jiangsu, China.
Shi Q; Department of Orthopedics, the First Affiliated Hospital of Soochow University, Orthopedic Institute of Soochow University, Suzhou, 215031, Jiangsu, China.
Gong YQ; Information Department, Affiliated Kunshan Hospital of Jiangsu University, Gusu School, Nanjing Medical University, Suzhou, 215300, Jiangsu, China.
Shao JW; Product R & D Department, Shanghai Fosun Health Technology Group Co Ltd, Shanghai, 200030, China.
Li C; Department of Orthopedics, Affiliated Kunshan Hospital of Jiangsu University, Gusu School, Nanjing Medical University, No. 91 West of Qianjin Road, Suzhou, 215300, Jiangsu, China. lichong1705@163.com.

Osteoporos Int ; 33(11): 2381-2396, 2022 Nov.

Article em En | MEDLINE | ID: mdl-35920895

Assuntos

Reação de Fase Aguda; Difosfonatos; Reação de Fase Aguda/induzido quimicamente; Cálcio; Difosfonatos/efeitos adversos; Humanos; Estudos Retrospectivos; Vitamina D; Ácido Zoledrônico

Palavras-chave

Acute-phase response; Osteoporosis; Prediction model; Zoledronate

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Reação de Fase Aguda / Difosfonatos Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google